相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer
Mari-Anne Rowlands et al.
CANCER CAUSES & CONTROL (2012)
Differences in phenotype and gene expression of prostate stromal cells from patients of varying ages and their influence on tumour formation by prostate epithelial cells
Yong-Chuan Wang et al.
ASIAN JOURNAL OF ANDROLOGY (2011)
The antiandrogenic effect of finasteride against a mutant androgen receptor
Yue Wu et al.
CANCER BIOLOGY & THERAPY (2011)
Insulin Increases De Novo Steroidogenesis in Prostate Cancer Cells
Amy A. Lubik et al.
CANCER RESEARCH (2011)
New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway
Gerhardt Attard et al.
CLINICAL CANCER RESEARCH (2011)
Insulin-like Growth Factor-2 (IGF2) Loss of Imprinting Marks a Field Defect Within Human Prostates Containing Cancer
Sachin Bhusari et al.
PROSTATE (2011)
Differential Mechanisms of Acquired Resistance to Insulin-like Growth Factor-I Receptor Antibody Therapy or to a Small-Molecule Inhibitor, BMS-754807, in a Human Rhabdomyosarcoma Model
Fei Huang et al.
CANCER RESEARCH (2010)
Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy
Danielle B. Ulanet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
Karen E. Knudsen et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2010)
Circulating insulin-like growth factor peptides and prostate cancer risk: A systematic review and meta-analysis
Mari-Anne Rowlands et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Aberrant epigenetic modifications in the CTCF binding domain of the IGF2/H19 gene in prostate cancer compared with benign prostate hyperplasia
Agnieszka Paradowska et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2009)
Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts
Jennifer A. Locke et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2009)
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
Joan M. Carboni et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions
A. Gualberto et al.
ONCOGENE (2009)
Insulin Receptor Expression by Human Prostate Cancers
Michael E. Cox et al.
PROSTATE (2009)
Insulin, insulin-like growth factors and neoplasia
Michael Pollak
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
A novel high-affinity peptide antagonist to the insulin receptor
Lauge Schaffer et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer
Jennifer A. Locke et al.
CANCER RESEARCH (2008)
Targeting insulin and insulin-like growth factor signalling in oncology
Michael Pollak
CURRENT OPINION IN PHARMACOLOGY (2008)
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Differential effect of proIGF-II and IGF-II on resveratrol induced cell death by regulating survivin cellular localization and mitochondrial depolarization in breast cancer cells
S. Kalla Singh et al.
GROWTH FACTORS (2007)
Insulin-like growth factor (IGF) 2 stimulates steroidogenesis and mitosis of bovine granulosa cells through the IGF1 receptor: Role of follicle-stimulating hormone and IGF2 receptor
L. J. Spicer et al.
BIOLOGY OF REPRODUCTION (2007)
IGF-II regulates metastatic properties of choriocarcinoma cells through the activation of the insulin receptor
L. E. Diaz et al.
MOLECULAR HUMAN REPRODUCTION (2007)
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer
M Stanbrough et al.
CANCER RESEARCH (2006)
IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging
L Trojan et al.
EUROPEAN UROLOGY (2006)
A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer
KN Chi et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer
MA Titus et al.
CLINICAL CANCER RESEARCH (2005)
Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871
BD Cohen et al.
CLINICAL CANCER RESEARCH (2005)
Mechanisms of the development of androgen independence in prostate cancer
A So et al.
WORLD JOURNAL OF UROLOGY (2005)
High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer
RA Sayer et al.
GYNECOLOGIC ONCOLOGY (2005)
The backdoor pathway to dihydrotestosterone
RJ Auchus
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2004)
Prostate specific antigen gene regulation by androgen receptor
J Kim et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2004)
Loss of IGF2 imprinting:: A potential marker of colorectal cancer risk
HM Cui et al.
SCIENCE (2003)
Loss of parental-specific methylation at the IGF2 locus in human hepatocellular carcinoma
K Poirier et al.
JOURNAL OF PATHOLOGY (2003)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer
SM Harman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2000)
分享论文
